Characterizing DNA methylation patterns in pancreatic cancer genome

Mol Oncol. 2009 Dec;3(5-6):425-38. doi: 10.1016/j.molonc.2009.03.004. Epub 2009 Apr 22.

Abstract

We performed a global methylation profiling assay on 1505 CpG sites across 807 genes to characterize DNA methylation patterns in pancreatic cancer genome. We found 289 CpG sites that were differentially methylated in normal pancreas, pancreatic tumors and cancer cell lines. We identified 23 and 35 candidate genes that are regulated by hypermethylation and hypomethylation in pancreatic cancer, respectively. We also identified candidate methylation markers that alter the expression of genes critical to gemcitabine susceptibility in pancreatic cancer. These results indicate that aberrant DNA methylation is a frequent epigenetic event in pancreatic cancer; and by using global methylation profiling assay, it is possible to identify these markers for diagnostic and therapeutic purposes in this disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / therapeutic use
  • Biomarkers, Tumor / genetics
  • Cell Line
  • Cluster Analysis
  • CpG Islands*
  • DNA Methylation*
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Epigenesis, Genetic
  • Female
  • Gene Expression Profiling / methods
  • Gene Expression Profiling / standards
  • Gene Expression Regulation, Neoplastic*
  • Genome*
  • Humans
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Oligonucleotide Array Sequence Analysis / methods
  • Oligonucleotide Array Sequence Analysis / standards
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / genetics*
  • Reproducibility of Results
  • Transplantation, Heterologous

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • Deoxycytidine
  • gemcitabine